简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
06
2026-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
05
2026-08
VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL
08
2026-07
VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)
06
2026-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026
02
2026-07
VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF PHASE II CLINICAL TRIAL APPLICATION FOR BA1106 IN COMBINATION WITH BA1104 FOR NSCLC
22
2026-06
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 JUNE 2026
11
2026-06
VOLUNTARY ANNOUNCEMENT LICENSING OF DULAGLUTIDE INJECTION IN THE U.S.
03
2026-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
29
2026-05
VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR TWO DENOSUMAB BIOSIMILARS IN THE U.S.
27
2026-05
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 22 JUNE 2026 (APPLICABLE TO HOLDERS OF H SHARES)
1
2
3
4
5
Follow me
鲁公网安备37069102000284